Variables | Survivors (n=56) | Non-survivors (n=38) | p Value |
Demographics | |||
Age (years) | 37 (2) | 37 (2) | 0.9615 |
Sex, male/female (n) | 17/39 | 17/21 | 0.1120 |
BMI (kg/m2) | 18.1 (0.3) | 18.4 (0.6) | 0.6202 |
Primary defect (n) | |||
ASD | 29 | 19 | 0.9642 |
VSD | 16 | 7 | 0.3077 |
PDA | 8 | 6 | 0.7609 |
Other | 3 | 6 | 0.0816 |
NYHA functional class (n) | |||
II | 35 | 7 | 0.0001 |
III | 21 | 25 | 0.0061 |
IV | 0 | 6 | 0.0017 |
Laboratory findings | |||
Packed cell volume (%) | 46 (1) | 49 (2) | 0.2624 |
Mean corpuscular volume (fl) | 91.4 (0.8) | 89.0 (1.2) | 0.1256 |
Serum creatinine (μmol/l) | 69.8 (2.7) | 82.2 (3.5) | 0.0081 |
Serum total cholesterol (mmol/l) | 4.20 (0.13) | 4.40 (0.16) | 0.3155 |
Triglycerides (mmol/l) | 1.04 (0.07) | 0.96 (0.06) | 0.7183 |
Fasting blood glucose (mmol/l) | 4.6 (0.1) | 4.4 (0.1) | 0.0724 |
Serum uric acid (mg/dl) | 5.9 (0.2) | 8.7 (0.4) | <0.0001 |
Haemodynamic variables | |||
mSAP (mm Hg) | 84 (2) | 82 (3) | 0.1915 |
mPAP (mm Hg) | 60 (3) | 69 (4) | 0.0396 |
CI (l/min/m2) | 2.9 (0.1) | 2.4 (0.1) | 0.0059 |
TPRI (Wood units/m2) | 23 (1) | 31 (2) | 0.0009 |
RAP (mm Hg) | 3 (1) | 5 (1) | 0.0165 |
PCWP (mm Hg) | 8 (1) | 6 (2) | 0.3911 |
Gas exchange (%) | |||
Arterial oxygen saturation | 87 (1) | 83 (1) | 0.0105 |
Mixed venous oxygen saturation | 65 (1) | 60 (1) | 0.0024 |
Treatment/procedures (n) | |||
Diuretics | 13 | 20 | 0.0019 |
Digitalis | 26 | 25 | 0.0962 |
Vasodilators | 7 | 4 | 0.8285 |
Anticoagulant agents | 7 | 7 | 0.3771 |
Venesections | 2 | 8 | 0.0054 |
Values are mean (SEM) except for numerical data.
ASD, atrial septal defect; BMI, body mass index; CI, cardiac index; mPAP, mean pulmonary arterial pressure; mSAP, mean systemic arterial pressure; NYHA, New York Heart Association; PCWP, pulmonary capillary wedge pressure; PDA, persistent arterial duct; RAP, right atrial pressure; TPRI, total pulmonary resistance index; VSD, ventricular septal defect.